申请人:Takeda Pharmaceutical Company Limited
公开号:EP1535915A1
公开(公告)日:2005-06-01
The present invention provides a compound represented by the formula (I):
[wherein R is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, p is 0, 1 or 2, and when p is 2, each R may be the same or different, R1 is a hydrogen atom or an optionally substituted hydrocarbon group, R2 is an optionally substituted aromatic group, Ring A is an optionally substituted monocyclic aromatic ring or optionally substituted bicyclic aromatic fused ring, X1 is an oxygen atom or a sulfur atom, X2 is a bond, an oxygen atom or -S(O)n- (wherein n is 0, 1 or 2), Y is a bond, an oxygen atom, -S(O)m-, -C(=O)-N(R3)- or -N(R3)-C(=O)- (R3 is a hydrogen atom, an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, and m is 0, 1 or 2), M1, M2 and M3 may be the same or different and are each independently a bond or an optionally substituted divalent aliphatic hydrocarbon group, and M4 is an optionally substituted divalent aliphatic hydrocarbon group] or a salt thereof, which is useful as a prophylactic and/or therapeutic agent for lipid metabolism abnormality, arteriosclerotic disease and sequelae thereof, diabetes mellitus and the like.
本发明提供了一种由式(I)表示的化合物:
[其中 R 为任选取代的烃基或任选取代的杂环基,p 为 0、1 或 2,当 p 为 2 时,每个 R 可以相同或不同,R1 为氢原子或任选取代的烃基,R2 为任选取代的芳香基、环 A 是任选取代的单环芳香环或任选取代的双环芳香融合环,X1 是氧原子或硫原子,X2 是键、氧原子或 -S(O)n- (其中 n 是 0、1 或 2),Y 是键、氧原子、-S(O)m-、-R3是氢原子、任选取代的烃基或任选取代的杂环基,m是0、1或2),M1、M2和M3可以相同或不同,各自独立地是键或任选取代的二价脂族烃基、和 M4 是任选取代的二价脂族烃基]或其盐,可用作脂质代谢异常、动脉硬化疾病及其后遗症、糖尿病等的预防和/或治疗剂。